| To observe the difference of thermally sensitized acupoint catgut embedding and Seretide in the treatment of chronic persistent bronchial asthma. Methods Sixty patients who met the inclusion criteria were randomly divided into treatment group (thermally sensitized acupoint catgut embedding method, 30 cases) and control group (seretide inhalation, 30 cases). Thermosensitized acupoint catgut embedding once a week; Seretide inhalation once a time, twice a day, for 3 months. The lung function (FEV1, PEF) and asthma control test (ACT) of the two groups were analyzed and compared after 3 months of treatment and 3 months of treatment respectively, and the clinical efficacy was statistically analyzed. Results At the end of 3 months of treatment, the pulmonary function and ACT score of the two groups were significantly improved (all P < 0.01), and there was no significant difference between the two groups (P > 0.05), indicating that the short-term efficacy of the two groups was basically the same; at the end of 3 months, the pulmonary function and ACT score of the thermally sensitized acupoint catgut embedding group maintained the level at the end of treatment, while the Seretide group decreased significantly, and the total of the thermally sensitized acupoint catgut embedding group was the The effective rate of 80% was significantly better than that of the Seretide group 53.4% (P<0.05), indicating that the thermally sensitized acupoint catgut embedding method had a more lasting effect and a better long-term effect.Conclusion Thermosensitized acupoint catgut embedding can effectively improve the lung function (FEV1, PEF) and clinical symptoms of patients with chronic persistent bronchial asthma. Its short-term efficacy is basically the same as that of Seretide, but its long-term efficacy is better than that of Seretide. |
